Precigen Inc (PGEN) Stock Analysis
Verdict: AVOID
PGEN trades near 52W highs on clinical expectations, but severe cash burn ($90M/yr) vs $30M cash signals imminent dilution risk.
Investment score: 35/100
Analysis as of
Is Precigen Inc stock worth reviewing? The TradeMates thesis
The TradeMates model assesses PGEN as high-risk with an imminent capital raising requirement, overriding bullish analyst price targets.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Precigen Inc opportunities and risks
What speaks for PGEN
- Phase 2/3 Clinical Advancements in UltraCAR-T and AdenoVerse Platforms
What speaks against PGEN
- Imminent Cash Depletion and High Dilution Risk
Frequently asked questions about Precigen Inc (PGEN)
Is PGEN stock a good investment?
The TradeMates model rates Precigen Inc as AVOID with an investment score of 35/100. The TradeMates model assesses PGEN as high-risk with an imminent capital raising requirement, overriding bullish analyst price targets. This is algorithmic model output, not personal investment advice.
Is PGEN stock a buy?
The TradeMates model verdict for PGEN is AVOID with an investment score of 35/100. Treat this as a model signal to review, not a personal buy recommendation.